Tarsus Pharmaceuticals (TARS) Tax Provisions (2020 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Tax Provisions of $2.4 million for Q1 2026, up 48100.0% quarter-over-quarter from -$5000.0 in Q3 2022.
Powered by 
Analysis
Tarsus Pharmaceuticals (TARS) Tax Provisions (2020 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Tax Provisions history runs 4 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Tax Provisions changed N/A year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (changed N/A YoY), while the FY2025 annual figure was $2.1 million, changed N/A from the prior year.
- Tax Provisions for Q1 2026 stood at $2.4 million, up from -$5000.0 in the prior quarter.
- The five-year high for Tax Provisions was $2.4 million in Q1 2026, with the low at -$5000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Tarsus Pharmaceuticals | 3.89 Bn | 3.44 Bn | 161.80 Mn | 2.72 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.72 Mn |
| Mar 31, 2026 | 2.40 Mn |
| Sep 30, 2022 | -5,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | 54,000.00 |
| Sep 30, 2021 | -341,000.00 |
| Jun 30, 2021 | 29,000.00 |
| Mar 31, 2021 | 313,000.00 |
| Sep 30, 2020 | 1,000.00 |